Exploring immune checkpoints as potential therapeutic targets in atherosclerosis

Area of Science:

• Cardiovascular Medicine
• Immunology
• Inflammation Biology

Background:

• Atherosclerosis is a major cause of death despite treatments for risk factors like high cholesterol and blood pressure.
• Chronic inflammation and immune cell interactions drive atherosclerosis development.
• Immune checkpoint proteins regulate immune cell interactions and are implicated in atherosclerosis.

Purpose of the Study:

• To review the role of immune checkpoint proteins in atherosclerosis.
• To explore therapeutic strategies targeting immune checkpoints for cardiovascular disease.
• To discuss challenges and novel approaches for immune checkpoint modulation in atherosclerosis.

Main Methods:

• Literature review of recent insights into immune checkpoint proteins in atherosclerosis.
• Analysis of the therapeutic potential of immune checkpoint modulators in experimental atherosclerosis models.
• Discussion of challenges and novel strategies for targeting immune checkpoints in cardiovascular medicine.

Main Results:

• Immune checkpoint proteins play a critical role in immune cell interactions that promote atherogenesis.
• Therapeutic strategies targeting immune checkpoints show promise but are largely confined to experimental settings.
• Novel approaches are being developed to leverage immune checkpoint modulation for atherosclerosis treatment.

Conclusions:

• Immune checkpoint proteins are key players in the inflammatory pathways of atherosclerosis.
• Targeting immune checkpoints represents a promising, albeit challenging, therapeutic avenue for cardiovascular medicine.
• Further research is needed to translate the success of immune checkpoint modulators from oncology to atherosclerosis treatment.